Inanovate’s Breast Cancer Monitoring Test
There were 235,030 new cases of breast cancer in the US in 2014. The 5-year survival rate for primary breast cancer is very good (98.6%) due to the effectiveness of breast exam and mammography. Unfortunately, following treatment of the cancer both breast exam and mammography are no longer effective. Instead, the standard of care for monitoring for breast cancer recurrence is a physical ‘check-up’ undertaken every 6 months following treatment (checking for signs of lymph node swelling, high temperature etc.). However, by the time physical symptoms arise, it is usually too late for effective treatment. As such 5-year survival plummets to 23.3%. Critically, if recurrence is detected in advance of physical symptoms survival rates are improved by up to 50%.
The Inanovate Solution
Inanovate is advancing a blood test to detect breast cancer recurrence in advance of physical symptoms. The test combines the Bio-ID with 7 (patent protected) breast cancer specific autoantibody biomarkers.
Cancer cells release biological molecules called tumor associated antigens (TAA’s). These in turn elicit an immune response and the release of antibodies that attack TAA’s. The detection of these antibodies (known as autoantibodies) provides a powerful mechanism for improved cancer diagnostics.
However, the implementation of this method has been severely restricted because existing biomarker analysis systems are unable to accurately and cost effectively detect and measure autoantibody biomarkers from complex samples like blood. Inanovate has solved this problem with the Bio-ID (click here for video demo)
In a 400 patient trial with our partner Sanford Health (one of the largest health systems in the US), our autoantibody biomarkers demonstrated the capability to identify breast cancer over healthy controls to a Sensitivity of 83% at a Specificity of 70%. This means that over 8 out of every 10 cases of cancer were correctly identified (a false negative rate of less than 2 in 10) with an associated false positive rate of only 3 in 10. If confirmed through our extended trials, such a test will have a very significant impact on clinical practice, saving tens of thousands of lives each year, and improving the quality of life for millions more.
Inanovate is now advancing through an extended 1,000 patient trial via our partnership with Sanford Health. If you would like to know how to get involved in helping advance this break-through test into clinical practice, and/or you would like further information on the Inanovate breast cancer monitoring test, including investment opportunities or partnering opportunities, please contact Inanovate at: [email protected].